What it's for (Indications)
- Immune globulin (IVIG) products are primarily indicated for a broad spectrum of conditions requiring immune modulation or passive antibody replacement.
- Key indications include the treatment of Primary Immunodeficiency Diseases (PIDD) where there is impaired antibody production, such as X-linked agammaglobulinemia or common variable immunodeficiency (CVID), to prevent recurrent infections.
- They are also used in various autoimmune and inflammatory disorders, including Idiopathic Thrombocytopenic Purpura (ITP) to increase platelet counts, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) to reduce neurological disability, and Kawasaki Disease to reduce the incidence of coronary artery aneurysms.
- Furthermore, IVIG is utilized in the management of Guillain-Barré Syndrome (GBS) and in specific scenarios for hematopoietic stem cell transplantation (HSCT) to prevent infection or graft-versus-host disease (GVHD).
- While Pentaglobin, as an example, is an enriched IgM/IgA preparation often used in severe bacterial infections or sepsis in immunocompromised patients, the general class of immune globulins covers a wider range of indications as mentioned.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of immune globulin is highly variable and depends significantly on the specific indication, patient weight, immune status, and the particular product formulation. It can range from 0.2 g/kg to 2 g/kg per course, administered either as a single dose, divided over several days, or given as monthly or weekly maintenance infusions. For instance, in PIDD, typical maintenance doses range from 0.4-0.8 g/kg every 3-4 weeks. For acute neurological conditions like GBS or CIDP, regimens often involve 0.4 g/kg daily for 5 consecutive days or 1 g/kg daily for 2 consecutive days. In ITP, dosages can be 1 g/kg for 1-2 days. The infusion rate typically starts slowly (e.g., 0.01 mL/kg/min) and is gradually increased if tolerated, to minimize infusion-related reactions. For products like Pentaglobin, used in severe infections, typical regimens might involve 5 mL/kg/day (equivalent to 0.25 g/kg/day of immunoglobulin) for 3 consecutive days. Dose adjustments may be necessary based on clinical response, tolerability, and specific laboratory parameters. |
Safety & Warnings
Common Side Effects
- Patients receiving immune globulin may experience a range of side effects, most of which are mild and infusion-related.
- Common adverse reactions include headache, flushing, chills, fever, malaise, fatigue, dizziness, nausea, vomiting, abdominal pain, diarrhea, back pain, myalgia, arthralgia, and skin rashes (e.
- g.
- , urticaria, pruritus).
- These reactions often subside with a reduction in infusion rate or administration of pre-medications such as antihistamines, antipyretics, or corticosteroids.
- More serious, albeit less common, adverse events warrant immediate medical attention.
- These include signs of renal dysfunction or acute kidney injury, symptoms indicative of thromboembolic events (e.
- g.
- , chest pain, shortness of breath, sudden numbness), aseptic meningitis syndrome (e.
- g.
- , severe headache, nuchal rigidity), and hemolytic reactions (e.
- g.
- , unusual fatigue, dark urine, jaundice).
- Anaphylactic reactions, while rare, are a severe concern, particularly in patients with IgA deficiency with anti-IgA antibodies.
Serious Warnings
- Black Box Warning: **THROMBOSIS** has been reported to occur following treatment with immune globulin products. Risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, and cardiovascular risk factors. For patients at risk of thrombosis, administer immune globulin products at the minimum dose and infusion rate practicable. Ensure adequate hydration prior to administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. **RENAL DYSFUNCTION AND ACUTE RENAL FAILURE** have been reported. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin products in predisposed patients. Risk factors for renal dysfunction include pre-existing renal insufficiency, diabetes mellitus, age >65, volume depletion, sepsis, paraproteinemia, and concomitant nephrotoxic drugs. For patients at risk for renal dysfunction or acute renal failure, administer immune globulin products at the minimum dose and infusion rate practicable. Ensure adequate hydration prior to administration. Consider assessing renal function, especially BUN/creatinine, before initiating therapy. Avoid products containing sucrose as a stabilizer in patients at risk for renal failure, as sucrose has been implicated in increased renal toxicity.
- Patients receiving immune globulin products should be closely monitored for adverse reactions during and after infusion.
- Infusion-related reactions such as chills, fever, headache, nausea, and flushing are common and often dose-dependent, typically managed by slowing the infusion rate or with pre-medication (antihistamines, antipyretics).
- However, more severe reactions requiring discontinuation may occur.
- **Aseptic Meningitis Syndrome (AMS)**, characterized by severe headache, nuchal rigidity, fever, photophobia, nausea, and vomiting, can occur hours to two days following treatment and typically resolves within several days of discontinuation.
- **Hemolysis** (e.
- g.
- , hemolytic anemia) has been reported, particularly in patients with non-O blood types and/or underlying inflammatory conditions; patients should be monitored for signs and symptoms of hemolysis (e.
- g.
- , decreased hemoglobin, jaundice).
- **Anaphylactic reactions** can occur, particularly in patients with IgA deficiency with anti-IgA antibodies.
- **Transfusion-Related Acute Lung Injury (TRALI)** has been reported, characterized by severe respiratory distress.
- **Volume overload** is a risk in patients with underlying cardiac or renal conditions, necessitating careful monitoring of fluid status.
- Patients should be adequately hydrated prior to administration to minimize the risk of adverse events, including renal dysfunction and thrombosis.
How it Works (Mechanism of Action)
Immune globulin products provide passive immunity by delivering a broad spectrum of immunoglobulin G (IgG) antibodies against a wide array of bacterial, viral, fungal, and parasitic antigens. This helps to neutralize pathogens and toxins, improving host defense in immunocompromised individuals. Beyond passive antibody replacement, immune globulins exert profound immunomodulatory effects. These mechanisms include blocking Fc receptors on macrophages, which reduces the clearance of autoantibody- or immune complex-coated cells (e.g., in ITP), modulating the production and function of cytokines, and downregulating the activity of B and T lymphocytes. They can also neutralize autoantibodies, suppress inflammatory responses, and activate the complement cascade. For specific preparations like Pentaglobin, which contain significant amounts of IgM and IgA in addition to IgG, there are additional mechanisms such as enhanced complement activation by IgM (important in severe bacterial infections) and mucosal immune defense provided by IgA, contributing to its efficacy in conditions like sepsis.
Commercial Brands (Alternatives)
No other brands found for this formula.